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The field of regenerative medicine (RM) is championed as a potential source of curative treatments and
economic wealth, and initiatives have been launched in several countries to facilitate innovation within
the field. As a way of examining the social dimensions of innovation within regenerative medicine, this
paper explores the sociotechnical representations of RM technologies in the UK, and the tensions,
affordances and complexities these representations present for actors within the field. Specifically, the
paper uses the Science and Technology Studies-inspired notions of ‘technology identity’ and ‘develop-
ment space’ to examine how particular technologies are framed and positioned by actors, and how these
positionings subsequently shape innovation pathways. Four developing RM technologies are used as case
studies: bioengineered tracheas; autologous chondrocyte implantation; T-cell therapies; and a ‘point-of-
care’ cell preparation device. Using these case studies we argue that there are particular identity aspects
that have powerful performative effects and provide momentum to innovation projects, and we argue
that there are particular stakeholders in the UK RM landscape who appear to have considerable power in
shaping these technology identities and thus innovation pathways.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Innovation in healthcare has become the subject of considerable
critical attention in many industrialised countries. Within political
and policy discourse, medical innovation is framed as providing
improved clinical outcomes and generating economic wealth, but
also as a problematic, complex process hindered by institutional,
regulatory and cultural constraints. This narrative is particularly
strong in the emerging field of regenerative medicine (RM), which
entails the use of cells, tissues or genetically-edited elements as
therapeutic agents. RM is championed as a potential source of
curative treatments for a wide range of ailments, and it has been
identified by governments as part of their economic growth stra-
tegies: the UK has identified RM as one of ‘eight great technologies’
which has the potential to become the basis of a high-wealth,
knowledge-based economy (Willetts, 2013). Initiatives have been
launched to identify innovation challenges within RM, and toGardner), rh955@york.ac.uk
, andrew.webster@york.ac.uk
r Ltd. This is an open access articledevise strategies for managing these (Department for Business
Innovation and Skills, 2011; UK Research Councils, 2012;
Regenerative Medicine Expert Group, 2015; House of Lords
Science and Technology Committee, 2013). The perceived chal-
lenges identified include: bureaucratic research governance
frameworks and inflexible clinical trial methodologies; a complex
and inconsistent EU-level regulatory framework; manufacturing
and scale-up of live-tissue production; uncertainties over cost-
effectiveness and reimbursement; the implementation of poten-
tially disruptive systems within busy, resource-strained clinical
contexts; and a lack of investment from private funders (Gardner
et al., 2015). Indeed, commentators have suggested that the
emerging RM field is to some degree incommensurable with the
current healthcare system and governance structures that have
emerged to accommodate drug and device-based therapies
(Omidvar et al., 2014).
In this paper, we explore the social and cultural dimensions of
innovation within the emerging field of RM, focusing predomi-
nately on developments in the UK. Specifically, we examine the
sociotechnical representations and positionings of RM technologies
to interrogate the tensions, affordances and complexities of inno-
vation in the field. To do so, we draw on and adapt Science andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and adoption space (Tomlin et al., 2013; Peirce et al., 2015; Ulucanlar
et al., 2013). The advantage of this framework is that it brings to
light the mutually configuring relationship between a technology
and actors in a specific sociotechnical context, and the effect that
this has on the technology's ongoing development. It enables us to
examine how RM technologies are understood by those in the field
in terms of perceived challenges, affordances and expectations, and
thus how innovation pathways are collectively negotiated. We use
these analytical concepts to explore four developing RM technol-
ogies: bioengineered tracheas; autologous chondrocyte implanta-
tion (ACI); T-cell therapies; and a ‘point-of-care’ cell preparation
device. Using these case studies we will show that there are
particular identity aspects that have powerful performative effects
and provide momentum to innovation projects, and we argue that
there are particular stakeholders in the RM landscape who appear
to have considerable power in shaping these technology identities
and thus innovation pathways.2. Innovation, technology, and identity
Technology identity and adoption space, as conceptualised by
Tomlin and colleagues (Tomlin et al., 2013), have their theoretical
foundations in sociology and in Science and Technology Studies
(STS). To introduce these concepts, we provide a summary of some
key theoretical tenets of these fields (and STS in particular) as they
relate to the study of innovation.
The most important of these tenets is relationality. According to
this, the meaning of an entity (whether it be a molecule, a technol-
ogy, or social organisation) is not the result of its inner ‘essence’;
rather, it is a consequence of its immersionwithin networks of other
technologies and systems of meaning making. These networks
render entities intelligible by foregrounding certain potentialities
(or what DeLanda (2006) has called capacities for interaction) and
endowing them with meaning, while eliding other potentialities
(Latour and Woolgar, 1986). In effect, then, the intelligibility of an
entity such as a healthcare technology depends on the context
within which it is immersed, and the same entity may be thus
rendered intelligible inmultiple ways. Hence, the second tenet is an
acceptanceofmultiplicity: co-existing socio-technical networksmay
produce divergent renderings, sometimes in tension with one
another (Mol, 2002; Pollock and Williams, 2010). Third, the defini-
tion of what constitutes an ‘actor’ does not exclude non-human en-
tities. A healthcare technology, for example, can be said to have
agency in that it prompts, guides, constraints and transmutes the
action of other entities including human agents (Latour, 2005). This
is not to say that such entities determine the action of others; rather,
an entity possesses affordances for further action, along with inter-
pretive flexibility (Pinch and Bijker, 1984) - the fourth tenet. This
means that precisely how an entity such as a healthcare technology
prompts actionwill depend on the local meaningswithinwhich it is
immersed. Combined, these tenets characterise the world as being
constituted by heterogeneous material and discursive networks
which produce and reproduce various kinds actors: technologies,
individuals, social groups, and so on (Law, 2008).
The concepts of technology identity and adoption space reflect
these key tenets. In their study of medical device adoption in
healthcare, Tomlin and colleagues argued that technologies acquire
particular identities that shape their adoption and dissemination
(Tomlin et al., 2013; Ulucanlar et al., 2013). Technology identities
are heuristic narratives; they are, as Ulucanlar and colleagues
define them:
A narrative or discursive presence of the technology that de-
lineates a particular set of attributed characteristics andperformative expectancies as representative of the technology's
distinctiveness and value (2013, 98).
Identities are forged and contested within what Tomlin et al.
(2013) define as the adoption space: the institutional context and
socio-political environment within which the technology is mobi-
lised. The former is composed of socio-technical infrastructures
including technologies and tools, protocols, professional interests
and institutional strategies, while the latter is composed of, for
example, media coverage, public attitudes, and political discourses.
Collectively, these elements imbue a technology with identity at-
tributes; they render it intelligible as being, say, ‘revolutionary’,
‘cost-effective’, ‘difficult to use’ or ‘implausible’, by foregrounding
some attributes of the technology while eliding others. Adoption
spaces are also dynamic: a new policy initiative, the emergence of
competing technology or some other contextual change may
radically affect a technology's identity. Importantly, these identities
inform decision-making processes regarding the adoption of the
technology in clinical contexts: they shape “perceptions in ways
that are instrumental in decisions about its use” (Ulucanlar et al.,
2013, 98).
We believe that with some minor adjustment, this framework
can provide a fruitful analytical vehicle for exploring healthcare
technologies that are still being developed. As the sociology of
expectations literature has made clear, the ‘momentum’ of inno-
vation is often the result of promissory, future-orientated repre-
sentations which function to align diverse interests (Borup et al.,
2006). This has certainly been the case with RM (Morrison, 2012;
Oerlemans et al., 2014; Gardner and Webster, 2016), characterised
by high expectations but no widely-implemented routine thera-
peutic technologies. We suggest that emerging RM technologies
inhabit a development space, conceptually complementary with the
notion of adoption space, but likely to include the characterisation
and positioning of novel technologies in anticipation of their
adoption in a clinical setting. It can be defined using a slightly
adjusted (in italics) definition of adoption space (Ulucanlar et al.,
2013, 98):
A spatial and temporal space transcending organisational and
geographic boundaries and populated by human and non-
human actors from different social worlds, where attitudes,
practices, interactions and events, together with the developing
technology's material features, shape technology perceptions in
ways that are instrumental in decisions about its further devel-
opment and use.
In this paper, we apply this analytical frame based on technology
identities and development spaces to interrogate four case-study RM
technologies and techniques. These are case studies which have
what can be described as promissory identities: considerable
(although not uncontested) high expectation surrounds their
envisaged potential.
The case studies are paradigmatic of emerging areas within RM:
they inhabit a field that is rich with ‘matters of concern’ (Latour,
2005), including, for example: the safety of therapeutic cells; the
acceptable level of uncertainty regarding clinical effectiveness,
safety, and cost effectiveness; and a concern that the promise of RM
will fail to materialise. Development spaces potentially include the
various bodies that have emerged to address such concerns (for
instance cell and tissue banks, and innovation accelerator
agencies), as well as pre-existing actors within the healthcare
landscape (regulatory agencies such as the European Medicines
Agency, patient charities, professional associations, hospitals,
health technology assessment bodies, and the media). RM
J. Gardner et al. / Social Science & Medicine 174 (2017) 70e7872technologies e such as the four examined here e are subject to
considerable speculation, assessment and forecasting, as stake-
holders attempt to reconcile conflicting values and establish viable
development pathways. We provide a detailed discussion of how
new technologies open up different spaces and pathways in the
biomedical economy. We identify those actors involved in the
problematisation (Callon, 1986) of the technology; that is, those
who are influential in defining the obstacles and affordances of a
technology to which subsequent actors must orient themselves.
3. Methods
Data for this paper were collected as part of the ESRC-funded
REGenableMED project. Around 70 semi-structured interviews
were conducted with scientists, clinicians, hospital managers,
regulators, economists, lawyers, patient advocacy and charity rep-
resentatives, professional associations, and company representa-
tives. The interviews explored respondents' perspectives on the RM
field, particularly in regard to innovation challenges, and tran-
scripts were systematically coded using NVivo9 software to identify
common themes. Various forms of publicly-available secondary
data were also examined, including company reports, meeting
minutes and media coverage. Data collection (including selection
and recruitment of participants) and analysis have been informed
by the project's Advisory Group, which includes representatives
from various stakeholder groups in the UK, including companies,
patient charities, accelerator agencies and the NHS. Ethics approval
for data collection was obtained from the appropriate institutional
ethics review board, and informed consent was obtained from all
participants.
The RM field is composed of an array of developments, which can
varyaccording to target indication, natureof the technologyplatform
(such as cell or tissue type), developmental stage, mode of
manufacturing, whether it is clinician-driven or commercially-
driven, and regulatory status. In light of these considerations, and
informedbyan analysis of initial interviewdata,weproduced a list of
eight possible technologies that represent emerging areas. With the
assistance of the Advisory Group, this list was narrowed to the four
selected case studies which are paradigmatic of different develop-
ment paths. Further interviewswere conducted in these four areas to
secure a set of views on each that is as comprehensive as possible.
While analysing the data, we drew on Ulucanlar and colleagues’
(2013) taxonomy of general technology identity dimensions. These
include: 1) the biography of the technology: narratives about its
plausibility and clinical rationale for its use, scope, and novelty, and
how these relate to its anticipated future; 2) the perceived clinical
and cost effectiveness of the technology; 3) the perceived utility of
the technology to advance clinical, professional or institutional
aims; and 4) the perceived risks of the technology as they relate to
clinical, financial or organisational aspects. In the following section
we provide a brief overview of each technology, noting key actors
within the development space. We then discuss in more depth
several technology identity characteristics, as they relate to this
taxonomy, which appeared to be particularly influential.
4. Findings
4.1. Bioengineered trachea
The bioengineered trachea is intended to replace severely
diseased or damaged trachea segments. It is being developed in the
UK by the Inspire Consortium which includes Videregen, a small
commercial enterprise; the NHS Blood and Transplant Service
(NHSBT), the Cell and Gene Therapy Catapult (CGTC), and scientists
and surgeons from two London hospitals. The trachea isconstructed from a cadaveric donor trachea (obtained by the
NHSBT), which is stripped of its cells using Videregen's decellu-
larisation technology platform, leaving a collagen scaffold. This is
reseeded with the recipient's bone marrow-derived mesenchymal
stem cells (which, ideally, form tracheal tissue) before being
implanted. It has been used in ‘compassionate-use’ cases: a 30 year-
old women in Spain in 2008, and a ten year-old boy in London in
2010. The technology has been subject to significant media
coverage, particularly around the two recipients who have been
described in some media as ‘doing well’. A Phase I clinical trial,
sponsored by the CGTC, is due to start soon in the UK, and as part of
a larger EU consortium, the project has been awarded a Horizon
2020 grant for Phase II clinical trials.
Our analysis of the portrayal of trachea identity dimensions
suggests that the key actors in the development space include
clinical innovators (‘champions’) and their institutions, news me-
dia, and the CGTC. One particularly influential identity aspect is its
perceived plausibility for addressing a severe unmet clinical need.
This is expressed in the rationale of one of the consortium's sur-
geons for becoming involved:
It was clear very early that the ways we had available to
reconstruct people after major head and neck surgery [for
cancer] were okay but left huge functional deficits and there
were some things we simply couldn't reconstruct, such as the
larynx and the trachea. (Consortium Surgeon)
This identity attribute has influenced the innovation pathway, in
that it provided a rationale for securing regulatory approval and
institutional support for the compassionate use cases:
Initial experiments were encouraging and so presented with a
sick lady in 2008 who had exhausted conventional options, we
got permission from the Spanish Health Ministry and interest-
ingly the Human Tissues Authority in the UK … Regulation au-
thorities were approached and approved. (Consortium Surgeon)
We were presented with a boy who had a terrible trachea
problem … he was at death's door and his tracheal stent had
eroded into his aorta … [since the implantation] he's done very
well… [it’s] certainly not ideal, but it saved his life. (Consortium
Surgeon)
The trachea has thus acquired a biography as a lifesaving tech-
nology, justifying its use despite some complications. This has
provided important affordances for the consortium: gatekeeping
actors (such as the Spanish Health Ministry and the UK's Medicines
and Healthcare Products Regulatory Agency) have reified this bi-
ography by permitting in-human use on compassionate grounds,
and this has enabled the consortium to gather information to
inform upcoming clinical trials (Surgeon, Interview). Influential
actors within the development space, particularly the surgeons’
host institutions and news media, have also framed the consor-
tium's trachea as ‘lifesaving’ (e.g. “desperate attempt to save his life
after other treatments failed …” (Daily Mail Reporter, 2012).
Additionally, these actors also frame the trachea as part of a
‘breakthrough’ (Roberts, 2008) or ‘pioneering’ (Adams, 2012)
transplantation procedure, conducted by a transplant team at elite
UK hospitals. This explicit framing links the success of the construct
to the reputation of the hospital and the surgical team e a link
which, according to a Videregen representative, has facilitated the
subsequent development of the trachea project:
We've got Professor [surgeon] who's the leading clinician… he's
a world leader so having him on the project … was a great
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places we wouldn't normally get to. (Videregen Rep1)
The reputation of the clinicians, then, contributes to the prom-
issory power of the trachea identity, and at the same time, the
reputation of host institutions as pioneers in regenerative medicine
is enhanced.
The ‘transplantation’ framing, with connotations of both ‘risk’
and ‘lifesaving’ is drawn upon by clinicians and scientists them-
selves. Here, a scientist involved in the trachea development re-
counts a conversation between himself and other clinicians:
A cardiac transplant surgeon said [to another surgeon] have you
any idea howmany heart transplants we did before the first one
worked? If anyone had said “I've only done two of these and 50%
of them died” I'm not going to do another one” it would never
have happened.
So the present-day high risk of the trachea transplantation
procedure is justified by the promise of a lower-risk future. This
framing supports a further aspect of the trachea's biography,
namely that it represents a gateway to a world of bespoke organ
generation:
“[This is] a demonstration project for us really to then show that
the technology platform works. We can then develop much
more complicated products to take forward.
The technique has thus acquired an influential biography as
being part of a lifesaving procedure, and as a testing and develop-
ment platform or gateway to bespoke organ generation. These dual
identity attributes appear to be providing significant momentum
by aligning disparate actors within the development space: regu-
lators, ‘highly reputable’ surgeons, commercial interests, and the
CGTC.
The trachea identity attributes recursively provide affordances
for other actors in the development space: for example, the con-
sortium's project appears to have an important strategic utility for
the CGTC. CGTC's stated rationale for their involvement refers to the
considerable potential (“estimated to be US $600million per year”),
and to the innovativeness of the project as a whole: “pathfinding
complex 3D manufacture and business models” (CGTC, 2014, 6).
The promissory biography of the trachea, in other words, aligns
with the national industrial strategy for generating ‘health and
wealth’. Importantly, this involvement in the trachea project is seen
by other partners as an endorsement which has led to further
funding (Videregen Rep1, Interview), including a substantial Hori-
zon 2020 grant for Phase II trials.
Nevertheless, despite the power of the trachea identity, the
plausibility and ‘lifesaving’ aspects are being contested. A scandal
has embroiled surgeon Paolo Macchiarini, who has allegedly
severelymisrepresented the poor clinical outcomes of patients who
received a synthetic trachea construct in Sweden and elsewhere.
Macchiarini and his host institution (the Karolinska Institute) had
been the subject of criticism from Pierre Delaere, professor of res-
piratory surgery at KU Leuven. Delaere has also criticised the
Inspire Consortium's project: the crux of his criticisms is that the
reseeded cells fail to sufficiently regenerate into vascularised tissue,
and that any therapeutic benefit derives from the stent that is used
to maintain an open airway (Delaere, 2010; Delaere and Van
Raemdonck, 2014). Some online science bloggers have adopted
Delaere's stance and are highly critical of the decellularised trachea
(e.g. Schneider, 2016). It remains to be seen if these contrasting
representations of the Consortium's bioengineered trachea willgain momentum and undermine the affordances being built
elsewhere.4.2. ACI: MACI/ChondroCelect/the OsCell method
ACI refers to a group of therapies for repairing cartilage damage
of the knee. Chondrocytes are extracted from the knee of the pa-
tient, expanded ex vivo, and then replanted into the damaged area.
Specific ACI therapies differ according to the duration of ex-vivo
expansion, and the means of re-administration. Two ACI tech-
niques have been commercialised: MACI (currently manufactured
by Aastrom) and ChondroCelect (developed by Tigenix). These are
two of the few RM products to have received marketing author-
isation from the European Medicines Agency under the Advanced
Therapy Medicinal Products (ATMP) regulatory framework. How-
ever, ACI has not been widely adopted due to difficulties securing
reimbursement arrangements: National Health Technology
Assessment agencies in France and the UK have stated that as yet
there is insufficient evidence, and in mid-2016 Chondrocelect was
withdrawn from themarket. In the UK, an additional ACI technique,
what we can call the ‘OsCell method’, has been developed within a
specialist clinical site, and is manufactured under a special ‘hospital
exemption’ licence (see Mahalatchimy et al., 2012).
The development space of these therapies includes professional
associations such as the British Orthopaedic Research Association
(BORS) and the British Association for Surgery of the Knee, and
particular Health Technology Assessment agencies such as the UK's
National Institute for Health and Care Excellence (NICE).
For clinical champions, an important aspect of the ACI biography
is its designation as a ‘regenerative’ or ‘cell-based’ therapy. In-
terviewees working within orthopaedics suggest that ACI repre-
sents a progressive step towards what they felt was the future of
bone and cartilage repair:
… metallic implants like total hip replacements and total knee
replacements are sort of done and dusted… optimized but they
haven't solved all of the problems. I think the only way to solve
those problems is to go to the biology of the system, and for that
reason, I think regenerative medicine is really important (BORS
rep1, Interview)
A recent editorial (McCaskie, 2015) in The Bone & Joint Journal
also makes this point, and the research charity Arthritis UK has
adopted this position, hence its funding of the UK Tissue Engi-
neering Centre. There is, then, some promissory momentum
behind RM within the orthopaedic field, and ACI is broadly asso-
ciated with this.
Another identity aspect of ACI relates to its perceived clinical
utility. Among orthopaedic clinicians ACI is seen as clinically useful
and appropriate for specific indications, but not a remarkable or
exceptional treatment. This is illustrated by the recent UK knee
surgeons’ consensus statement on management of articular carti-
lage defects of the knee (Biant et al., 2015). The statement argues
that:
For lesions 2e4 cm2 in the average sized knee, [ACI] is the most
effective treatment option based on the published literature …
Lesions > 4cm2 … studies suggest that cell therapy is the best
evidence-based treatment in this situation.
It adds that conventional therapies are more appropriate for
lesions of other sizes, and that available evidence suggests that for
some outcome measures, there is no difference between ACI and
conventional therapies at five years after treatment. Such
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but certainly not e currently - a radical improvement over other
options.
The consensus statement illustrates a wider tension concerning
the clinical effectiveness identity dimension of ACI. Evidence of
clinical effectiveness was deemed sufficient by the European
Medicines Agency to demonstrate that the “benefits are greater
than its risks”. The EMA also stated, however, that “knowledge of
the long-term effect of the medicine is limited” (EMA, 2014, 3). This
has been emphasised by other gatekeeping actors, and ACI has
obtained a potentially influential uncertain long-term effectiveness
identity aspect as a result. The significance and implications of this
identity aspect differ across healthcare contexts. In the UK, it was
consolidated in a recent, publicly available, NICE cost assessment
(NICE, 2015). A positive recommendation would have led to
nationwide commissioning in England. However, based on an
appraisal of current evidence of ChondroCelect, MACI and the
OsCell method, the draft guidance states that ACI “is recommended
only in research”. The findings state that data on clinical effec-
tiveness were heterogeneous and of mixed quality, some of which
was poor quality due to “small sample sizes” and “inadequate du-
rations of follow-up”. Similarly, long term cost-effectiveness of ACI
was uncertain as “each study lacked long-term clinical follow-up
data and good quality of life data” (NICE, 2015, 18). The British
Association for Surgery of the Knee has expressed its disappoint-
ment in the draft assessment and is encouraging ACI recipients to
submit comments in support of ACI to NICE (BASK, 2015).
Within the UK, then, this uncertain long term effectiveness
identity of ACI has hindered its dissemination in the NHS. The
emphasis placed on this identity aspect differs among actors within
the development space. Health insurance companies, for example,
had agreed to fund ChondroCelect for private patients in the UK.
Gatekeeping actors in other health jurisdictions have also fore-
grounded other identity aspects: in the Netherlands, for example,
the promissory value of ACI as an RM was reflected in the inclusion
of ChondroCelect on a special reimbursement scheme (“Beleids-
regel Dure Geneesmiddelen”) for innovative medical technologies.
Nevertheless, the uncertain long term effectiveness identity
dimension has, recursively, had a significant effect on companies
involved in ACI: due to the inability to secure widespread reim-
bursement for their product, TiGenix initiated the withdrawal of
their product from marketing authorisation for ‘commercial rea-
sons’, and is instead focusing on a different RM technology platform
to “deliver shareholder value” (Globe Newswire, 2016).
What we see here, then, is that ACI has been endowed with a
complex identity by various actors: it has some promissory value,
but it is not considered to be particularly radical. It is considered
useful and appropriate for some indications, but its long-term
clinical effect is uncertain. The emphasis placed on each of these
aspects differs among various decision-making actors within the
development space, meaning that ACI techniques have been na-
tionally reimbursed in some countries but not others.
4.3. CAR T-Cells
Chimeric Antigen Receptor, or ‘CAR’, T-Cell therapies are im-
munotherapies that treat cancer. Donor (allogeneic) or recipient
(autologous) T-Cells are isolated and genetically reprogrammed to
recognize malignant cells, triggering a targeted immune response.
Promising recent results have generated considerable interest in
the area (Vertes, 2016), and in the UK it was used as an exemplar to
test the suitability of NICE's technology appraisal methodology for
assessing RM treatments. Worldwide there are dozens of clinical
trials testing CAR T-Cells, mostly for blood cancers, but also for
glioma, glioblastoma, and other head and neck cancers. Many aresponsored by small companies working in conjunction with
research-intensive hospitals, although recently large pharmaceu-
tical companies have also become involved.
The development space for CAR T-Cell therapies is thus consti-
tuted by a range of actors including clinicians and their research
hospitals, SMEs, big pharma, and the media. Additionally, an
important feature of the development space is the biomedical
infrastructure that has emerged to diagnose and manage blood
cancers and autoimmune conditions, much of which is managed by
NHSBT (in the UK) and Haematological services. This infrastructure
has provided a structuring platform for further innovation (Keating
and Cambrosio, 2003), and this is reflected in the emergence of T-
Cell immunotherapies: NHSBT, for example, has established a Stem
Cell and Immunotherapy Research Unit with University College
London. One consequence is that subpopulations of T-Cells can be
relatively easily isolated, identified and quantified using existing
processes. As one interviewee noted:
You can grow them up to a precise number, more or less anyway,
and then you can also follow them in the patient. And you can
follow the different … sub-sets, and you can also characterise
the different sub-sets, in the lab and in the patient …
(Researcher/Clinician, Interview).
Thus among some actors, CAR T-Cells have acquired an identity
as being delineable and thus monitorable e characteristics that
relate to their risk identity dimension, which are important also for
designing protocols for clinical studies, particularly for monitoring
safety.
The technology's biography is dominated by ‘remarkable’ results
of early clinical studies, generating considerable enthusiasm. Here,
a clinician reflects on recent clinical studies for ALL:
We're talking about patients with terminal [acute lymphoblastic
leukaemia] for whom there is no treatment … Phase 1 clinical
trials with an 80% complete response rate, achieving complete
sustained clinical remission… I've never seen anything like it in
my life … normally, a new agent in a Phase 1, if you get a 10%
response rate that's probably as good as it gets. (Clinician,
Interview)
As with the bioengineered trachea, CAR T-Cell technology has
acquired a biography as a lifesaving technology. This aspect has
been reinforced by other actors within the development space,
particularly the media. One commentary noted:
“Among several dozen patients who would typically have only
had months to live, early experimental trials that use the im-
mune system's T-Cells to target cancers had ‘extraordinary re-
sults’. In one study, 94% of participants with [acute
lymphoblastic leukaemia] saw their symptoms completely
vanish” (Yuhas, 2016).
Another article, which covers the case of a young child, states:
“Layla Richards had one of the worst cases of leukaemia her
doctors had ever seen and, when all other treatments failed, her
parents were told to expect the worst… thanks to an infusion of
50 million cells genetically engineered to hunt and kill the
cancer, the disease has vanished and she is happy …” (MacRae,
2015)
These quotes also highlight another key aspect of CAR T-Cell
biography: the use of military terms to describe its mode of action,
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carry significant emotional weight. CAR T-Cells are thus cast as an
ally in a biomedical-moral war against cancer, and in some coverage,
as a potential cure for cancer. Emotive titles include: “The Future of
Cancer Treatment is Here, and it is Really Saving lives” (Plenke,
2016); and “Extraordinary Treatment Could be Cancer Break-
through” (Jha, 2016).
Like the trachea, CAR T-Cells have also acquired a biography as a
gateway technology. Academic literature highlights the potential
for directing CAR T-Cells to a range of antigens, and corporate actors
appear to have been influential in mobilising and taking advantage
of this promissory identity dimension. In corporate representa-
tions, CAR T-Cells are framed as a multivalent technology platform
which can be targeted towards various cancer types. This aspect
appears to have provided momentum to commercial alliances that
include big pharmawhich, in the past, has been reluctant to engage
in the ‘uncertain’ field of RM. This is illustrated by the collaboration
between Celectis, University College London, and Pfizer on the
allogenic product UCART19, which was developed as an ‘off-the-
shelf’ product by Cellectis and used in a high-profile compassionate
use case involving a terminally-ill one year old girl with relapsed
acute lymphoblastic leukaemia, who now appears to be cancer-
free. The agreement means that Pfizer has the exclusive rights to
develop and commercialise UCART directed at 15 specific cancer
targets, while Celectis will develop and commercialise UCART
directed at eight different cancer targets (Pfizer, 2014). Celectis and
Pfizer, then, have been brought together by the perceived multi-
valency of UCART - which they anticipate will lead to multiple,
legally-delineable and commercially lucrative markets. Indeed, it
appears that the identity features of CAR T-Cells are providing
significant affordances for big pharma.4.4. Celution System (Cytori)
The Celution system is produced by Cytori, a US-based company
focusing on cosmetic and reconstructive surgery. Celution is a
closed, automated system for processing a patient's adipose tissue
to obtain regenerative cells which can be used for several in-
dications. Cell processing takes less than two hours, enabling it to
be carried out at the ‘point-of-care’ during a surgical operation. The
system corresponds to a ‘bench-top’ device: a centrifuge and
electronic display are housed within a casing, which contains clips
for a standardized, single-use disposable processing set. It is used in
post-cancer breast reconstruction at several clinical sites in the UK,
and in studies on treatments for fistulaein-ano, chronic wounds,
chronic ischemic heart failure, and scleroderma (an autoimmune
condition). Celution is regulated as a medical device within the EU.
Generally the medical device regulatory pathway is considered less
onerous than the EU's ATMP framework. Consequently, the system
can be used without the need of a high-cost clinical-grade Good
Manufacturing Practice facility. Similarly in the US, the extracted
cells do not fall within the remit of the FDA's Cellular and Gene
Therapy Pathway and such a facility is not required, though the
regulatory pathway can be more onerous than that in the EU
(Kramer et al., 2012): the device has conditional FDA approval for
use within clinical trials. Influential actors in the development
space of the Celution System include the manufacturer Cytori,
regulators, and the clinical teams and institutions that are using
and trialling the device.
Cytori and clinician-users are attempting to actively shape the
biography of the system by emphasising its plausibility as a means
of producing therapeutically useful regenerative material. These
actors refer to this material as ‘adipose-derived’ regenerative cells,
described as a heterogeneous cell population that includes:not just [adipose-derived stem cells], but also a substantial
number of other cell types of therapeutic potential, including
vascular endothelia cells, tissue macrophages and so forth
(Fraser et al., 2014, 39).
Multiple mechanisms of therapeutic action are claimed,
including “potential to improve outcome by replacing cells lost to
injury, disease, and daily wear and tear” (Cytori, 2016). Hence, the
system is represented as a means of obtaining and concentrating a
clinically useful substance. A clinician interviewee who uses the
device referred to it as ‘turbo-charged’ with regenerative material.
In breast reconstruction, the interviewee added, this meant that the
reconstruction procedure only required one graft, rather than e as
in some cases e several. It thus provides an important opportunity
for clinicians and their institutions to become involved in ‘RM’,
without the need for an expensive manufacturing facility. Addi-
tionally, commercial and clinical actors emphasise the potentially
wide range of indications that can be treated: wound care, auto-
immune conditions, and heart failure. The system, then, has a bi-
ography in which it is presented as having a wide clinical scope.
Commercial and clinical-academic actors also emphasise the
system's organisational affordances by framing it as producing
regenerative cells in a standardized, automated fashion. It is thus
positioned as being a relatively quick procedure “that can be used
in a real time bedside manner” (Fraser et al., 2014, 38), or “at the
point of care (in theatre, at the bed side, or within a hospital)”
(Cytori, 2013). Here, its identity aligns with an envisaged ideal in
RM: that current, labour-intensive and expensive open RM pro-
duction systems will be replaced with closed automated systems.
According to an interviewee, such organisational affordances had
facilitated the adoption of the systemwithin her hospital. Very little
additional training is needed to use the device, nurses had been
trained to use it, and it was possible to conduct other clinical work
while the device was processing the regenerative material (Sur-
geon, Interview, written notes).
There is some tension relating to the cost of the device and the
perceived cost effectiveness of the procedures in which it is used.
One actor, the UK's NHS National Innovation Centre, conducted a
cost-assessment of the System in breast reconstruction, concluding
that it could lead to “significant cost savings for the NHS” (Winn,
cited in Cytori, 2011). Yet, it has not beenwidely adopted within the
NHS, probably because payers (hospitals and trusts) believe the
initial cost to be too high. NICE has not recommended it. A clinician
interviewee believed this was one reason why there had been
reluctance within her institution to purchase the System. However,
it was eventually purchased when clinicians working in other dis-
ease areas expressed a desire to use it (Surgeon, Interview, written
notes). Its eventual adoption was thus influenced by its promissory
identity of having several therapeutic applications.
Regulators are particularly influential actors within the devel-
opment space of the Celution System. The implications of being
classified as a medical device differ between the EU and the US, as
indicated by marketing authorisation in the former but not the
latter. In the US, its relative novelty and ‘innovativeness’ were at
issue. If the device is considered significantly different from exist-
ing in-use devices (‘predicate devices’), then it requires a PMA (pre-
market approval) with stringent data requirements, generally
necessitating clinical trials. Cytori attempted to avoid this by
framing their system as being sufficiently similar to existing devices
that are used to draw and concentrate haematopoietic stem cells,
thus constructing a biography of significant homology with existing
devices and thus being of limited novelty. The FDA however dis-
agreed, identifying the system as being sufficiently novel as to
warrant a PMA. As a result, while the device is essentially ‘on the EU
J. Gardner et al. / Social Science & Medicine 174 (2017) 70e7876market’ for certain indications, in the US it has acquired an identity
as investigational with an uncertain safety and efficacy profile.
5. Discussion
The approach we have adopted here enables us to go beyond the
usual policy discoursewhich presents innovation as being a process
of identifying and overcoming technical and organisational chal-
lenges. We have used the notion of technology identities as an
analytical frame for interrogating how expectations, identities and
interests become entwined, and how innovation trajectories are
forged as a result. We have focused on specific instances with a
select though important group of technologies, and it is important
to recognize the limitations of this narrow focus. However, in each
of the case studies above, we see how technology identities are
negotiated, maintained and in some cases contested by various
actors within the development space, and hence how particular
development pathways are collectively negotiated and enacted.We
see that some technologies such as ACI acquire complex, contested
identities which appear to limit their development and adoption,
and we see that others, such as the trachea and the CAR T-Cells,
acquire powerful promissory aspects that align diverse actors,
providing momentum to further development and adoption. A
summary of influential identity aspects is presented in Table 1.
The case studies indicate that within the field of RM, particular
actors are more powerful than others in shaping influential tech-
nology identities and, consequently, development pathways. Pio-
neering clinicians, clinicians' academic and clinical institutions, andTable 1
Influential identity aspects of four RM technology case studies.
Technology/technique Useful exemplar because … Relational id
Bioengineered trachea Surgeon-led development:
Project is heavily dependent on surgical
skill;

















MACI & ChondroCelect have received
marketing authorisation;
Have undergone formal health
technology appraisals;








CAR T-cells A major area of activity within the field
of RM;
Represents high proportion of current
clinical trials in RM;
Represents a potential cure for some
cancer types;











Celution ‘Point of care’ system An automated close-system for cell
processing;
Classified as a medical device;











frameworknews media play an important role in framing and perpetuating
technology identities, but unsurprisingly, regulatory agencies and
HTA authorities are particularly powerful actors in shaping tech-
nology identities within the development spaces of RM. Identity
aspects relating to regulatory classifications and comparative cost-
effectiveness have major implications for the decision-making of
other actors within the development space, and national differ-
ences between such agencies (and the different weightings placed
on particular identity aspects) are reflected in the variation in
development pathways across countries: the national commis-
sioning of ChondroCelect in the Netherlands and not the UK is an
example of this, as is the differing regulatory status of the Celution
System in the UK and the US. Regulatory and HTA agencies are,
then, powerful, authoritative actors in the problematisation
(Callon, 1986) of emerging RM technologies: they delineate and
define the technology, prompting other actors to orientate them-
selves accordingly. These problematisations may be perceived by
other actors as creating barriers to further development and
adoption of the technology, but they also present affordances;
affordances that can lead to novel development trajectories for
technologies endowed with particular identity aspects. For
example, compassionate use of technologies classified as ATMPs is
permitted by the EMA's ATMP framework (via ‘exemptions/spe-
cials’ schemes) which allows a clinician to prescribe them as a
lifesaving measure on a one-off basis. In effect, this provides a
development pathway for technologies with durable identities as
being ‘lifesaving’. This is illustrated by the bioengineered trachea
case: as a ‘plausible lifesaving’ technology, it was permitted for in-entity aspects, including summary (bold). Powerful actors involved in
problematisation.
chnology
nsplantation procedure conducted at elite
;
hnology that leads to a future of immune-
bespoke organ generation;
technology for establishing a thriving RM
the UK
ny actors, it has an influential but contested
y as lifesaving and as a promissory gateway to
ovation. Presents affordances for
l actors.
Regulators (European







ul, but not remarkable/exceptional
ng-term effectiveness;
in the development space foreground
entity aspects, leading to a complex &
dentity that has led to variable uptake.
Regulators (European







iomedical-moralwar against cancer - a potential
multivalent, gateway technology;
ny actors, it has an influential dual identity as
nd as a multivalent, gateway technology.
‘multivalent’ has facilitated innovation
Regulators (European




Corporate actors e big pharma
ans of producing regenerative material;
wide scope of applications;
n as a medical device producing non-ATMP
e material;
al affordances/utility;
e, yet too costly;
novel to require PMA (in USA);
sents affordances for clinicians but not
their institutions. Different regulatory
s have fostered a variable technology identity.
Regulators, particularly
European Medicines Agency,
Food & Drug Administration
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formation to inform subsequent clinical trial protocols. The in-
human use generated media attention, and consolidated this
identity, no doubt facilitating subsequent innovation alliances.
Similarly, compassionate use of CAR T-Cell technology resulted in
significant, highly optimistic media representations. We suggest,
then, that compassionate use represents a significant development
trajectory within the field of regenerative medicine.
It has been argued that the success of an innovation depends on
its capacity to appeal to, and be co-opted by, the interests of a
diverse range of actors (Brown and Webster, 2004). In the field of
RM, we see that technology identity aspects such as ‘lifesaving’
resonate with the values and interests of actors (particularly gate-
keeping actors), thus facilitating further development and poten-
tial adoption. In the case of CAR T-cells, this identity has been
positionedwithin the culturally-resonant biomedical-moral war on
cancer, providing it with additional symbolic potency. Another
important identity aspect relates to the perceived scope of the
technology. We showed that the Celution system has yet to be
widely adopted, but its adoption in one clinic was justified by its
multiple clinical and research applications. In particular, a dual
identity as being both a current lifesaving technology, and a
promissory gateway technology that will lead to further thera-
peutic and commercial opportunities, is a powerful dynamic
aligning diverse actors, as illustrated by both the trachea and CAR-T
Cells. The perceived multivalent potential of CAR T-Cells, for
example, has led to new innovation alliances involving big pharma
(Pfizer), smaller SMEs (Celectis) and research-intensive hospitals.
Both the trachea and CAR T-Cell identities also have strategic utility
for institutions: they represent affordances which enable a clini-
cian's host institutions, for example, to present themselves via
press releases as being at the forefront of RM. Additionally, we see
that the trachea project has received support for a UK state-
supported RM accelerator: it resonates with the CGTC's mandate
to facilitate translation and commercialization. The establishment
of the CGTC has, in effect, meant that an additional set of interests
relating to industry building, wealth generation and national
prosperity have become particularly influential elements of the
development spaces within the field of RM.
We also see in the case studies that negotiations over appro-
priate development pathways can centre on the relative novelty of
a technology. As much of the literature in the sociology of expec-
tations has demonstrated (Borup et al., 2006; Brown and Michael,
2003), the delineation of a technology as ‘novel’ and ‘innovative’
can often provide momentum to its development or adoption by
aligning actors - the decision of the Dutch authorities to fund
ChondroCelect as an ‘innovative new therapy’ is an example.
Studies have also illustrated that technologies with indistinct
identities, or identities as being little different to other technologies
(Ulucanlar et al., 2013), can limit their uptake. However, the cases
studies presented here illustrate that actors may also strategically
foreground such homologies. The trachea, for example, has ac-
quired an identity as being part of a ‘transplantation technique’,
relating it to the history of other transplantation procedures. Actors
may contest the relative novelty/homology of the technology,
resulting in the consolidation of a particular identity and corre-
sponding pathway: The debate between Cytori and the FDA over
the Celution System and its similarity with existing systems, and
the resulting decision that a PMAwould be required for the system,
is an example of this.
Finally, we also see technology identities have been constructed
that affirm national political imaginaries of ‘health and wealth’.
Both the bioengineered trachea and CAR T-Cell identities, for
example, align with the commercialization innovation trajectory
envisaged within UK Government's strategic ‘Eight GreatTechnologies’ policy (Willetts, 2013). However, as the ACI example
illustrates, constructed identities can reflect tensions between such
imaginaries and the State's role in governing access to new medi-
cines. State-endorsed identity constructing mechanisms such as
negative cost-effectiveness assessments can effectively bring
dissemination to a halt.References
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